Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 195 |
| Active Pipeline (Recruiting Now) | 122 (81) |
| Completed vs Stopped Early | 8 / 3 (1.5%) |
| Median Closed Actual Enrollment | 58 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| The Second Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou | 20 |
| The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, Zhejiang | 17 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07575672 | Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure | Phase III | RECRUITING |
| NCT06375005 | Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis | Phase II | RECRUITING |
| NCT07022223 | Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma | Phase II | RECRUITING |
| NCT04879615 | 24 Hours Treatment with Alteplase in Patients with Ischemic Stroke | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Second Affiliated Hospital, Zhejiang University, School of Medicine Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.